A Medical Device Daily
Anika Therapeutics (Bedford, Massachusetts), a developer of products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, has terminated its U.S. distribution contract with ArtesMedical (San Diego) for Elevess , its injectable dermal filler that reduces the appearance of lines and wrinkles on the face.
This follows Artes Medical's disclosure that it has initiated a significant workforce reduction, and that it has not been able to address its anticipated liquidity issues.
Anika said it values the customers for the product and will continue efforts on its own to service these customers while actively seeking a new partner for the U.S. distribution of Elevess, which was the first HA-based dermal filler approved by FDA to incorporate the anesthetic lidocaine to improve patient comfort.
As a result of the termination of the U.S. distribution agreement, Anika expects that it will not be able to achieve between $1 million and $1.5 million in Elevess revenue for 2008 as previously forecast.
In addition, Anika said it continues to focus on signing international distributors for Elevess. In 3Q08, the company reported exclusive agreements with three new dermatology-focused distributors to market Elevess in Mexico, Chile, Peru and South Korea. The agreements provide exclusive distribution rights for Elevess in each of these markets.
In other agreements/contracts news, Premier (San Diego) reported agreements for the new dialysis products category have been awarded to B.Braun Medical (Bethlehem, Pennsylvania), MedicalComponents (Harleysville, Pennsylvania) and Covidien (Mansfield, Massachusetts).
Effective Nov. 1, the 36-month agreements are available to acute-care and continuum-of-care members of the Premier healthcare alliance.